biomx logo  May 15, 2017BiomX Ltd., an Israeli microbiome therapeutics company, announced today that it has raised $24 million in a Series A funding round. The round was led by OrbiMed, Johnson & Johnson Innovation – JJDC, Inc. and Takeda Ventures, Inc. with participation from Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors. BiomX, previously named MBcure, was founded in the FutuRx Ltd. incubator, with the support of the Israel Innovation Authority.